Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice.
Level 5 - mechanism / opinion, no new human data
Animal and in vitro mechanistic laboratory study
PubMed 12939405 · doi:10.1073/pnas.1434398100
What was done
The authors investigated the enzymatic mechanism underlying carboxyl-terminal cleavage of apolipoprotein E (apoE) and generated transgenic mice expressing the cleavage fragment, apoE4(Δ272-299), at high or low levels in the brain to assess neuropathology and behavioral outcomes in vivo.
What was found
Proteolysis of apoE was attributed to a chymotrypsin-like serine protease that cleaves apoE4 more efficiently than apoE3. Mice expressing high brain levels of apoE4(Δ272-299) died at 2-4 months of age, displaying cortex and hippocampus neurodegenerative changes including hyperphosphorylated tau and Gallyas silver-positive neurons containing 15-20 nm cytosolic filaments. Transgenic mice with lower expression survived longer but developed learning and memory deficits at 6-7 months of age. No exact sample sizes, numerical values, or statistical metrics were reported in the abstract.
Why it matters
This study provides in vivo evidence that carboxyl-terminal-truncated fragments of apoE4 are sufficient to induce Alzheimer's disease-like neurodegeneration and cognitive impairment, identifying a potential mechanistic target for intervention.
Limits
The abstract provides no sample sizes, numerical data, effect sizes, or variance measures. As an animal model and cell culture study, direct applicability to human Alzheimer's disease progression and clinical outcomes remains unproven.
Cited by
- context Research from the Gladstone Institutes shows APOE4 exhibits a dominant negative effect where the protein is cleaved and forms aggregates that activate microglia and trigger an inflammatory cascade in the brain.